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Abstract
Screening and evaluating anti- hepatitis C virus (HCV) drugs in vivo is difficult worldwide, mainly because of the lack of
suitable small animal models. We investigate whether zebrafish could be a model organism for HCV replication. To achieve
NS5B-dependent replication an HCV sub-replicon was designed and created with two vectors, one with HCV ns5b and
fluorescent rfp genes, and the other containing HCV’s 59UTR, core, 39UTR and fluorescent gfp genes. The vectors containing
sub-replicons were co-injected into zebrafish zygotes. The sub-replicon amplified in liver showing a significant expression of
HCV core RNA and protein. The sub-replicon amplification caused no abnormality in development and growth of zebrafish
larvae, but induced gene expression change similar to that in human hepatocytes. As the amplified core fluorescence in live
zebrafish was detectable microscopically, it rendered us an advantage to select those with replicating sub-replicon for drug
experiments. Ribavirin and oxymatrine, two known anti-HCV drugs, inhibited sub-replicon amplification in this model
showing reduced levels of HCV core RNA and protein. Technically, this method had a good reproducibility and is easy to
operate. Thus, zebrafish might be a model organism to host HCV, and this zebrafish/HCV (sub-replicon) system could be an
animal model for anti-HCV drug screening and evaluation.
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Introduction
Current therapy for HCV infection is the combination of
Pegylated-interferon (PEG-IFN) with ribavirin [1,2]. This regimen
has only suboptimal clinical efficacy and is with side-effects [3,4].
It is widely agreed that a suitable small animal model for HCV
replication would significantly accelerate discovery of new drugs
against HCV. Although investigation on mouse HCV models is
progressing, the results were far from satisfactory [5]. Transgenic
mice made with HCV genetic elements were created in order to
identify HCV pathogenic components, and were short of HCV
enzyme-controlled viral replication [6–9]. All of the HCV
infection mouse models need surgical operation to inoculate
human liver cells into recipient organs [8]. Difficulties of using the
models include complicated surgical procedures, genetic variation
of the clinical HCV isolates, low and/or unstable HCV infection
rate, low HCV viraemia [10,11], as well as the safety concerns that
arise from the dangers of HCV transmission to research personnel
via rodent bite during experiments. These obstacles have largely
restricted the use in drug testing [11]. Novel, small and easy-to-
handle model organism for in vivo HCV replication represent a
pressing need for anti-HCV drug discovery.
HCV belongs to the Flaviviridae family and has a single-stranded
positive RNA genome [12]. HCV genome encodes a single open
reading frame (ORF) and is translated into a polyprotein, which is
cleaved into four structural proteins (core, E1, E2 and p7) and six
non-structural ones (NS2, NS3, NS4A, NS4B, NS5A and NS5B)
[12]. Among these factors, NS5B is necessary for viral replication
with essential assistance from 59UTR (IRES) and 39UTR [13,14].
NS5B is a 65 kD viral RNA-dependent RNA polymerase (RDRP).
It recognizes specific RNA 39UTR sequence and initiates HCV
replication for the negative strand RNA, which then works as a
template to create positive strand of RNA for HCV assembly,
therefore completing the amplification of HCV genetic materials
[12]. During this process the 39UTR is a crucial element for HCV
replication [15]. Based on the functions of the above mentioned
HCV elements, a HCV sub-genomic replicon (sub-replicon) was
designed and created in our laboratory. In selecting host recipients
for the HCV sub-replicon, zebrafish as a vertebrate came to our
attention. Zebrafish has been used to the study of human diseases
[16–18]. As zebrafish has a good homology to human in genetics,
particularly in liver [18], and is small and easy-to-handle in
laboratory, we explored its potential of being a model organism for
HCV replication. In what follows we show that zebrafish could be a
potential small animal model for replication of the HCV sub-
replicon and used in drug evaluation.
Materials and Methods
Plasmids
HCV 1b (J4L6s) strain (accession no. AF054247) was from Dr.
HS Chen (Peking Union Medical College, Beijing, China). NS5B
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the downstream of the CMV promoter in the pIRES2-DsRed
(Fig. 1a). The prGC3N was constructed with the negative
sequence of EGFP-IRES (form pIRES2-EGFP) and HCV core-
59UTR in a reverse-direction, and then, a positive strand HCV
39UTR was attached to the 59UTR in a forward-direction (Fig. 1a).
The construct of prGC null of HCV 3 `UTR (Fig. 1a) served as a
control. All of the constructs were confirmed by DNA sequencing.
Zebrafish microinjection and fluorescent microscopic
examination
Adult zebrafish (Danio rerio) AB line were obtained from Dr.
Anming Meng (Tsinghua University, Beijing, China) and received
human care and that study protocols comply with the institutions
guidelines. Zebrafish were maintained in a controlled environment
with 14-h light/10-h dark cycle at 2861uC. The HCV sub-
replicon zebrafish was made with co-injection of the prGC3N and
p5BR into the blastomere at the early 1–8 cell-stage embryos at a
concentration of 1 ng/ml of the construct DNA. Larvae positive
for both GFP and RFP fluorescence were examined at 8 and 12
days post fertilization (dpf), using fluorescence microscopy with the
GFP (480 nm excitation, 505 nm emission) and RFP filters
(556 nm excitation, 586 nm emission), respectively.
Reverse transcription - polymerase chain reaction (RT-
PCR)
Larvae total RNA was isolated with Trizol Reagent. The cDNA
was synthesized from 1 mg of the total RNA using AMV reverse
transcriptase (Promega). The primers used were given in Table 1.
The target cDNA templates were amplified by PCR with Taq
polymerase (TaKaRa, Japan). PCR was performed with 0.5 ml
cDNA and primer pairs of core, ns5b and b-actin, using a
program of 94uC for 5 min, 94uC for 60 s, 55uC for 30 s and 72uC
for 1 min. After 30 cycles, the reaction mixtures were incubated at
72uC for an additional 10 min to allow a complete synthesis. The
RT-PCR products were subjected to 1.5% agarose gel electro-
phoresis. b-actin was used as control.
Quantitative real time RT-PCR
The study RNA was reversely transcribed into cDNAs first.
Then, the cDNA templates were used for quantitative PCR
reaction. It was performed using the SYBR green technique in the
Bio-Rad CFX96 system (Bio-Rad, Hercules, CA). Core and b-
actin cDNA were detected with Platinum SYBR Green qPCR
SuperMix-UDG kit (Invitrogen). Primers were designed with
Primer 5.0 (Premier Co., Canada). The primers for core and b-
actin cDNA detection included b-actin qF, b-actin qR and core
qF, core qR (Table 1). Thermocycling conditions were the
following, 5 min at 95uC, then 40 three-temperature reaction
cycles with 30 s at 95uC, 30 s at 55uC and 30 s at 72uC. The data
were analyzed using Bio-Rad CFX96 software. The copy number
of the study genes in the untreated zebrafish larvae was defined as
1, and the numbers of gene copies in the treated larvae were
plotted relative to that value.
Western blotting
Zebrafish larvae protein was extracted with lysis buffer and
separated in the 12% SDS-PAGE. The protein bands were
transferred onto a nitrocellulose membrane followed by blocking.
The membranes were incubated with anti-core or anti-NS5B
antibodies (Abcam Co.) at 1:2000 dilutions in TBS containing 1%
skim milk; then the membrane was washed and incubated with
HRP-conjugated goat anti-mouse or goat anti-rabbit IgGs (1:2000
dilutions, Zhongshanjinqiao Co.) for 1 hr at RT. Proteins were
Figure 1. Zebrafish as a model organism for HCV sub-replicon amplification. a. The HCV sub-replicon was created with prGC3N and p5BR
vectors. Cartoons are for vector prGC3N, prGC and p5BR. CMV promoter was for transcription. prGC3N has a gfp-IRES(EMCV)-core-59UTR sequence
that was reversely inserted at the downstream of CMV promoter and followed by a HCV 39UTR sequence in a forward direction; prGC has no HCV
39UTR; the p5BR is a functional vector carrying HCV RNA polymerase (NS5B) and RFP. b. Co-injection of the sub-replicon into zebrafish zygote
blastomere. c. Fluorescent microscopy examination for HCV core protein amplification in zebrafish liver using a GFP filter (480 nm excitation, 505 nm
emission; image, 100X). d. Fluorescent RFP filter (556 nm excitation, 586 nm emission) was used to detect liver HCV NS5B protein signal in red. e. The
whole mount in situ nucleic acid hybridization was used to detect the positive strand of HCV core RNA, in order to confirm the green fluorescent
signal for the replication of the HCV sub-replicon.
doi:10.1371/journal.pone.0022921.g001
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substrate (Thermo) with AlphaEaseH FC Imaging System (Alpha
Innotech Corporation).
Whole mount in situ hybridization
Core (nt 430–702) and ns5b (nt 8067–8459) sequence of the
J4L6 strain were used as templates for hybridization probe
synthesis, using DIG RNA Labeling Kit (Roche Diagnostics
Scandinavia AB, Bromma, Sweden). Whole mount in situ
hybridization was performed as previously described [19,20].
Briefly, 10-dpf larvae were fixed with 4% paraformaldehyde for
10 hrs at 4uC and washed with 16PBST. The larvae were treated
with proteinase K and DNase I separately, pre-hybridized in 65uC
for 4 hrs, and hybridized with the RNA probe at 65uC overnight.
The residual probe was washed with 0.26SSC, followed by
incubating with anti-Dig-AP (Roche) at 4uC over night. After wash
with 16PBST, the samples were colorized with BCIP/NBT for
30 min and stopped with 16PBST washing. The larvae were
observed with light microscope.
Drug treatment
Ribavirin and oxymatrine were from National Institutes for
Food and Drug Control (Beijing, China). Ribavirin at a final
concentration of 1000, 100 and 10 mg/ml, or oxymatrine at a final
concentration of 200, 20 and 2 mg/ml was added into the
zebrafish cultivation water, and incubated for 5 days (from 5 dpf
to 10 dpf). Then, the larvae were collected for analysis.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Regulation for the Management of
Laboratory Animals of the Ministry of Science and Technology of
China. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Institute of Medicinal
Biotechnology, Chinese Academy of Medical Sciences
(IMBF20060302).
Results and Discussion
Replication of fluorescence-labeled HCV sub-replicon in
zebrafish larva
The fluorescence-labeled HCV sub-replicon was designed and
constructed with a pair of vectors; one vector contained HCV core
gene, 59UTR sequence and fluorescent gfp in a reverse-direction to
the CMV promoter, as well as a 39UTR sequence in a forward-
direction; and the other one contained fluorescent rfp and HCV
ns5b genes (Fig. 1a). The two vectors in 1:1 ratio were co-injected
into zebrafish zygotes under microscope (Fig. 1b). By principle, the
CMV promoter should initiate the transcription for the negative
strand RNA of gfp-IRES-HCV/Core-59UTR with a downstream
sequence of the positive strand HCV 39UTR RNA, which is for
NS5B to recognize. Subsequently, the positive strand HCV core
mRNA and gfp mRNA should be generated by NS5B (red signal)
through a HCV 39UTR-mediated amplification, and then
translated into core and GFP proteins with a demonstration of
green fluorescent signal. The green signal of GFP showing
replication of the HCV sub-replicon (Fig. 1c) and red signal of
RFP (Fig. 1d) for NS5B protein translation should be visible in live
zebrafish under fluorescent microscope, if the sub-replicon
amplifies in a sufficient amount. It allows us to select live zebrafish
with active HCV sub-replicon amplification to enter into drug
experiments. Amplification of the HCV sub-replicon in zebrafish
liver could be confirmed by whole mount in situ nucleic acid
hybridization which is used to test the presence of the positive
strand HCV core mRNA (Fig. 1e).
The experimental results are shown in Fig. 2a. Eight days after
co-injection of the prGC3N and p5BR vectors, both green and red
fluorescence was detected in the liver location of zebrafish,
indicating a 39UTR-mediated amplification of the HCV sub-
replicon. The successful rate of sub-replicon amplification was
seen in about 30% of the zebrafish zygotes co-injected with
prGC3N and p5BR. Control larva groups injected with prGC or
prGC3N alone showed neither green nor red fluorescent signal;
co-injection of prGC and p5BR which was null of the 39UTR
sequence exhibited red signal only. These results indicate that the
green signal from the larvae co-injected with prGC3N and p5BR
vectors represents the sub-replicon replication mediated through
an interaction between HCV 39UTR and NS5B. The experiment
has been repeated over 7 times. The result suggests that this sub-
replicon device encloses functional elements for HCV amplifica-
tion in this model organism host.
To verify replication of the HCV sub-replicon in this model,
HCV core mRNA and protein in the zebrafish larvae was isolated
and examined with RT-PCR as well as Western blot. As shown in
Fig. 2b, the negative strand HCV core RNA was detectable in all
of the groups injected with prGC, or prGC3N, or prGC plus
p5BR, or prGC3N plus p5BR, indicating an active transcription
for the negative strand core RNA in these zebrafish larvae (Fig. 2b).
Table 1. Primer sequences for PCR reaction.
Primer Sequences
Core F 59-AGCGGTCGCAACCTCGTGGAA-39
Core R 59-GCGGAAGCTGGGATGGTCAAAC-39
NS5B F 59-GCTCGCCTTATCGTATTCC-39
NS5B R 59-AGTCGTCAGCACGCCAC-39
Gfp F 59-ACGGCGTGCAGTGCTT-39
Gfp R 59-TGGGTGCTCAGGTAGTGG-39
3UTR-R 59-ACATGATCTGCAGAGAGGCCAGTAT-39
b-actin-F 59-AGGGAAATCGTGGGTGACATCAAA-39
b-actin-R 59-ACTCATCGTACTCCTGCTTGCTGA-39
Chemokine20F 59-TCTCTTCTCACCTGCCCTAA-39
Chemokine20R 59-ATTGCTTGCACCTTCTCCCTC-39
AHSG F 59-GGAAGGCAGCGGTGAAA-39
AHSG R 59-ATGGTCTGGCCCGAGTG-39
Hsp70 F 59-GCGACACCTCTGGAAAC-39
Hsp70 R 59-TGCTCAGCCTGCCCTTG-39
Rasgbd F 59-ATCCCTCAACTTCCCACC-39
Rasgbd R 59-TCTGCCTGCTCCACCTC-39
Argsyn F 59-GACAGGACGAGGACTTTG-39
Argsyn R 59-TGACGGGAACAGGAATG-39
ScarF2 F 59-CTCTTGCGTCTACAGGG-39
ScarF2 R 59-GCTCAGCGGTTTCTATT-39
Leugpcr F 59-GGTGTTTGTCTGGGTTG-39
Leugpcr R 59-GGTCTGAGTGAAGAGGGA-39
b-actin qF 5 `-TCTGGTGATGGTGTGACCCA-3 `
b-actin qR 5 `-GGTGAAGCTGTAGCCACGCT-3 `
Core qF 5 `-GCGACAACCTATCCCAAAG-3 `
Core qR 5 `-CCCAAGTTACGCGACCTAC-3 `
doi:10.1371/journal.pone.0022921.t001
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the zebrafish larvae co-injected with prGC3N and p5BR
(prGC3N/p5BR group), but not in those injected with prGC or
prGC3N alone, or p5BR and prGC in combination (prGC/p5BR)
(Fig. 2b). The results were further confirmed at protein level using
Western blot assay, showing the HCV CORE protein signal
presented only in the prGC3N and p5BR co-injection group
(Fig. 2c). To learn the time-dependent dynamics, amplification of
the sub-replicon was followed up for 10 days after prGC3N/p5BR
co-injection. As shown in Fig. 2d, the level of HCV core mRNA
significantly increased along with time, indicating an active
amplification process of the HCV sub-replicon in larvae liver.
Figure 2. Amplification of the HCV sub-replicon in liver of the zebrafish larvae. a. HCV sub-replicon amplified in those co-injected with
prGC3N and p5BR vectors. Green fluorescence represents the NS5B-dependent HCV core protein products of the sub-replicon (prGC3N/p5BR); red
fluorescence indicates the presence of the NS5B enzyme. Arrows point the positive signals in liver area. WT, untreated control. b. RT-PCR
measurement for the amplification of the study genes in the sub-replicon. Core+, the positive strand of HCV core RNA; core-, the negative strand of
HCV core RNA; ns5b, HCV ns5b from p5BR; and beta-actin, loading control. WT, wild type. c. Western blot for HCV core and NS5B proteins with anti-
core or anti-NS5B antibody, respectively. Beta-actin was loaded as a control. d. Amplification of the HCV sub-replicon exhibits a time–dependent
increase from 4- to 10-dpf in zebrafish larvae for the positive strand of core RNA; negative strand core RNA and beta-actin remains to be constant.
dpf, day post fertilization. e. Confirmation of the time–dependent amplification of the HCV sub-replicon with quantitative real time RT-PCR for the
positive strand of HCV core RNA. f. Whole mount in situ hybridization of the co-injected zebrafish. Whole mount in situ hybridizations were carried
out on 10-dpf larvae using antisense or sense RNA probes. The presented are original microscopy images of the zebrafish larvae (80X). dpf, day post
fertilization.
doi:10.1371/journal.pone.0022921.g002
Zebrafish as an Animal Model for HCV Replication
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22921The amplification kinetics was validated with real time RT-PCR
(Fig. 2e).
The green and red fluorescent signal localized mainly in the
liver area of the larva body (Fig. 2a), indicating a liver-selective
tendency of the HCV sub-replicon. To further verify the
selectivity, in situ hybridization was done for the whole larva body
10 day post fertilization using core and egfp nucleic probes. The
goal is to learn the in vivo distribution of the sub-replicon products.
As shown in Fig. 2f, the positive strand HCV core RNA signal,
probed with negative strand core sequence, was detected only in
the larvae co-injected with prGC3N/p5BR vectors, and concen-
trated in the liver area of the larvae, providing a supportive result
for that in Fig. 2a. As a matter of fact, in the prGC3N/p5BR
group the signal detected with either positive and/or negative
strand nucleic acid sequences for core or GFP presented
predominantly in larva liver area, with very weak signal in
intestine (Fig. 2a). Wild type larvae were without signal (Fig. 2a).
The experiment was repeated 3 times. Detection of HCV core
expression in zibrafish organs was not done in this study because
the larvae at 10 days were about 4 mm in length, too small to
precisely separate their organs.
Biological impact on zebrafish larva after prGC3N/p5BR
co-injection
Body length and phenotype were compared between wild type
larvae and those co-injected with prGC3N/p5BR. As shown in
Fig. 3a, amplification of HCV sub-replicon did not slow down the
growth of the larvae (p.0.05) at least in the first 12 days of
embryonic development; deformity phenotypes were not observed
as well (Fig. 3b). The results indicated that development and
growth of the zebrafish at the stage from zygote to larva was not
interrupted by the prGC3N/p5BR co-injection or the subsequent
HCV sub-replicon amplification. The sub-replicon positive
zebrafish survived throughout the larva stage (for at least 12 days).
HCV infection causes host gene expression alteration in human
liver cells. The reported genes up-regulated by HCV infection
includes chemokine-1 1igand (chemokine-l) [21], Solute carrier
family 2 (ScarF2) [22], Leucine-rich repeat-containing G protein-
coupled receptor 5 (Leugpcr) [23], Alpha2-HS glycoprotein
(AHSG) [24], heat stress protein 70 (Hsp70) [25], Ras-related
GTP binding D (Rasgbd) [23], Argininosuccinate synthetase 1
(Argsyn) [23], as well as profibrogenic molecules like TGF-b,
PDGFs, and VEGF [26] et al. Thus, our next experiment is to
learn whether, or not, replication of the sub-replicon in larvae
causes such change in these genes. RT-PCR was done for the
study genes. The results are shown in Fig. 3c. Eight and twelve
days after co-injection of the prGC3N/p5BR vectors the
expression of Argsyn, Hsp70, Leugpcr, ScarF2, Rasgbd and
chemokine-1 genes in the larvae increased as compared to the
untreated wildtype controls; but the AHSG gene appeared being
down-regulated. For the profibrogenic molecules, TGF-b in-
creased but the expression change of PDGFa and VEGFb was not
obvious in this study. The results in zebrafish basically agreed with
that in HCV infected human liver cells [23,27], showing a similar
transcription impact on the host. These results suggest that
zebrafish liver might have an intracellular circumstance supportive
for HCV replication and comparable to that in human
hepatocytes.
Anti-HCV drug evaluation using zebrafish as a model
organism
Next, we tested if the zebrafish HCV sub-replicon model was
suitable for evaluation of anti-HCV drugs. The test compounds
were ribavirin and oxymatrine. Ribavirin is currently the first-line
clinical drug for HCV [28]. Oxymatrine is also an agent active
against HCV replication in hepatitis C patients and has been used
in Chinese hospitals [29]. Good water-solubility was another
reason to select the two drugs. In this experiment, the drugs were
added into the incubation water of the sub-replicon positive
zebrafish larvae on day 5 of the embryonic development, with 20
zebrafish larvae in each treatment group. The experiment was
followed up for 5 days. None of the larvae died during the
Figure 3. Biological effects on zebrafish larvae after injection of the HCV sub-replicon. a. Body length of the wild type larvae and those
co-injected with prGC3N/p5BR. b. Phenotype of wild type larvae and those co-injected with prGC3N/p5BR. The scales represent 500 um. c. Expression
of the HCV-associated genes in zebrafish larvae. The mRNA level of the study genes were examined with RT-PCR reaction in wild-type and the
prGC3N/p5BR co-injection larvae (8 dpf and 12 dpf).
doi:10.1371/journal.pone.0022921.g003
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doses. The larvae were taken for total RNA extraction on day 5
post drug treatment. As shown in Fig. 4a, incubation of the larvae
in the ribavirin- or oxymatrine-containing water for 5 days largely
inhibited the amplification of the HCV core RNA indicated by
positive strand of the sub-replicon. The inhibition was in a dose-
dependent manner both in ribavirin and oxymatrine treated
groups. Ribavirin at 100 mg/ml or oxymatrine at 20 mg/ml, or
higher, significantly suppressed the replication of the HCV sub-
replicon. The negative strand core RNA was exhibited as a
reference in the figure in order to show a successful co-injection of
the prGC3N/p5BR vectors into the zebrafish zygotes (Fig. 4a).
Real time RT-PCR assay showed a similar result (Fig. 4b). The
treatment efficacy of the drugs on HCV RNA was confirmed at
protein level using Western blot (Fig. 4c). The results indicate that
the zebrafish-hosted HCV sub-replicon amplification system
appears to be a suitable animal model to evaluate anti-HCV
drugs or drug candidates, especially for water-soluble agents.
Fig. 4d demonstrates measurement of the larva body length at the
end of the experiments and showed that neither ribavirin nor
oxymatrine at the doses used caused reduction of the larva body
length, verifying good safety of the drugs in clinic. Also, no
deformity phenotypes were observed in the treated larvae.
The present study provides evidence that zebrafish liver cells
might contain biological circumstances comparable to that of
human hepatocytes. It could be one of the explanations of why
zebrafish liver is permissive for human HCV amplification. Results
from cancer study have drawn similar conclusion [18]. To the best
of our knowledge this is the first report using zebrafish as an in vivo
model organism to host HCV amplification and to evaluate anti-
HCV drugs. In creating HCV sub-replicon inoculated zygotes, it is
our experience that about 250 zebrafish zygotes could be injected
per hour by a well-trained researcher, and the successful rate of
injection is approximately 90%; among these zygotes about 30%
turn out to be positive for the sub-replicon amplification. It enables
us to obtain a good number of zebrafish larvae for experiments. As
compared with mouse HCV models [5,10,30,31], this model
organism has at least the following advantages in drug test. First,
the procedure of creating the sub-replicon positive larva is not
complicated; second, the HCV RDRP-dependent sub-replicon
replicates actively and steadily in zebrafish liver; third, the
designed GFP fluorescent signal in live zebrafish for HCV core
Figure 4. Ribavirin and oxymatrine inhibited amplification of the HCV sub-replicon in zebrafish larvae. Zebrafish larvae co-injected
with prGC3N/p5BR were treated with ribavirin or oxymatrine respectively from 5-dpf to 10-dpf, followed by biological measurements. a. Conventional
RT-PCR for anti-HCV effect of the study drug. Core+: the positive strand of core RNA; core-: negative strand of HCV core RNA. b. Real time RT-PCR
examination for anti-HCV effect of the study drug. Core+: the positive strand of core RNA. c. Western blot assay for HCV core and NS5B proteins in the
zebrafish larvae treated with ribavirin or oxymatrine. Core was detected with anti-HCV core antibody; beta-actin was with anti-beta-actin antibody
(used as a control). d. Body length (mm) of the co-injected zebrafish larvae treated with the study drug (ribavirin or oxymatrine). Wild type larvae are
shown as reference.
doi:10.1371/journal.pone.0022921.g004
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replicon amplification to enter into drug experiments; and forth,
this easy-to-handle small biological model seems to be suitable for
drug screening, with no need to concern about the safety issues
that arise from possible animal bite. The major disadvantages of
this model are that 1) the HCV sub-replicon is eventually an
artificial sub-virus and not the natural HCV, and 2) it is probably
only suitable for water-soluble drugs and the dose calculation is not
convenient. Currently, we are exploring the possibility of growing
full genome HCV in zebrafish model.
Ribavirin and oxymatrine are known drugs for HCV in clinic
[28,29]. The anti-HCV efficacy of ribavirin is statistically
significant [32,33], although the molecular mechanism in its
action against HCV remains to be clarified. Oxymatrine is an
alkaloid extracted from the plant Kushen (Sophora flavescens Ait)
[34]. Clinical studies in China has showed that injection of
oxymatrine (0.4 g/d for 6 months) in chronic hepatitis B (CHB)
patients caused over 40% of the patients to become negative for
HBV DNA [35], and viral load measurement showed that
oxymatrine injection (0.4 g/d for 3 months) decreased HBV viral
load by about 2logs in average [36]. Further clinical investigations
showed that oxymatrine (0.6 g/per, intramuscular injection for 3
months) also inhibits HCV replication in hepatitis C patients
causing negative conversion of HCV RNA in about 30% of the
patients [37]. In the present study, the two drugs were used as
positive references to evaluate the zebrafish HCV model. Indeed,
both drugs demonstrated an inhibiting effect on the replication of
the HCV sub-replicons in this model organism at RNA as well as
protein levels. The results agree with that observed in hepatitis C
patients [33,37]. In addition, the two drugs showed no toxicity to
the larvae during the treatment, consistent with the safety record
of the drugs in clinic [35,38]. This drug experiment validates the
usefulness of this model organism in anti-HCV drug evaluation.
We consider the zebrafish HCV sub-replicon model a valuable
tool with significant potential of being used to screen and evaluate
anti-HCV drugs.
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